Contact, publication, and social network information about Harvard faculty and fellows. Harvard Catalyst Profiles
Keywords
Last Name
Institution

Naoto Hirano, PH.D., M.D.

TitleAssistant Professor of Medicine
InstitutionDana-Farber Cancer Institute
DepartmentMedicine
AddressDana-Farber Cancer Institute
Medical Oncology
450 Brookline Ave
Boston MA 02215
Phone617/632-6186
Fax617/632-2255

 Bibliographic 
 selected publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
List All   |   Timeline
  1. Butler MO, Hirano N. Human cell-based artificial antigen-presenting cells for cancer immunotherapy. Immunol Rev. 2014 Jan; 257(1):191-209.
    View in: PubMed
  2. Butler MO, Imataki O, Yamashita Y, Tanaka M, Ansén S, Berezovskaya A, Metzler G, Milstein MI, Mooney MM, Murray AP, Mano H, Nadler LM, Hirano N. Ex vivo expansion of human CD8+ T cells using autologous CD4+ T cell help. PLoS One. 2012; 7(1):e30229.
    View in: PubMed
  3. Imataki O, Ansén S, Tanaka M, Butler MO, Berezovskaya A, Milstein MI, Kuzushima K, Nadler LM, Hirano N. IL-21 can supplement suboptimal Lck-independent MAPK activation in a STAT-3-dependent manner in human CD8(+) T cells. J Immunol. 2012 Feb 15; 188(4):1609-19.
    View in: PubMed
  4. Nakatsugawa M, Yamashita Y, Hirano N. [The cutting edge of antitumor adoptive cell therapy]. Rinsho Ketsueki. 2011 Oct; 52(10):1713-20.
    View in: PubMed
  5. Tanaka M, Butler MO, Ansén S, Imataki O, Berezovskaya A, Nadler LM, Hirano N. Induction of HLA-DP4-restricted anti-survivin Th1 and Th2 responses using an artificial antigen-presenting cell. Clin Cancer Res. 2011 Aug 15; 17(16):5392-401.
    View in: PubMed
  6. Kojima S, Nakao S, Young N, Bacigalupo A, Gerard G, Hirano N, Maciejewski J, Deeg J, Marsh J, Zhang FK, Lee JW, Ozawa K. The Third Consensus Conference on the treatment of aplastic anemia. Int J Hematol. 2011 Jun; 93(6):832-7.
    View in: PubMed
  7. Butler MO, Friedlander P, Milstein MI, Mooney MM, Metzler G, Murray AP, Tanaka M, Berezovskaya A, Imataki O, Drury L, Brennan L, Flavin M, Neuberg D, Stevenson K, Lawrence D, Hodi FS, Velazquez EF, Jaklitsch MT, Russell SE, Mihm M, Nadler LM, Hirano N. Establishment of antitumor memory in humans using in vitro-educated CD8+ T cells. Sci Transl Med. 2011 Apr 27; 3(80):80ra34.
    View in: PubMed
  8. Butler MO, Ansén S, Tanaka M, Imataki O, Berezovskaya A, Mooney MM, Metzler G, Milstein MI, Nadler LM, Hirano N. A panel of human cell-based artificial APC enables the expansion of long-lived antigen-specific CD4+ T cells restricted by prevalent HLA-DR alleles. Int Immunol. 2010 Nov; 22(11):863-73.
    View in: PubMed
  9. Yoshimi A, Kojima S, Hirano N. Juvenile myelomonocytic leukemia: epidemiology, etiopathogenesis, diagnosis, and management considerations. Paediatr Drugs. 2010; 12(1):11-21.
    View in: PubMed
  10. Ansén S, Butler MO, Berezovskaya A, Murray AP, Stevenson K, Nadler LM, Hirano N. Dissociation of its opposing immunologic effects is critical for the optimization of antitumor CD8+ T-cell responses induced by interleukin 21. Clin Cancer Res. 2008 Oct 1; 14(19):6125-36.
    View in: PubMed
  11. Yoshida N, Yagasaki H, Takahashi Y, Yamamoto T, Liang J, Wang Y, Tanaka M, Hama A, Nishio N, Kobayashi R, Hotta N, Asami K, Kikuta A, Fukushima T, Hirano N, Kojima S. Clinical impact of HLA-DR15, a minor population of paroxysmal nocturnal haemoglobinuria-type cells, and an aplastic anaemia-associated autoantibody in children with acquired aplastic anaemia. Br J Haematol. 2008 Jul; 142(3):427-35.
    View in: PubMed
  12. Butler MO, Lee JS, Ansén S, Neuberg D, Hodi FS, Murray AP, Drury L, Berezovskaya A, Mulligan RC, Nadler LM, Hirano N. Long-lived antitumor CD8+ lymphocytes for adoptive therapy generated using an artificial antigen-presenting cell. Clin Cancer Res. 2007 Mar 15; 13(6):1857-67.
    View in: PubMed
  13. Hirano N. Anti-gamma-globin adoptive cell therapy for the treatment of juvenile myelomonocytic leukemia. Hematology and Oncology. 2007.
  14. Ansén S, Butler MO, Berezovskaya A, Murray AP, Nadler LM, Hirano N. IL-21 can directly enhance the expansion of antigen-specific CD8+ T cells with a distinct phenotype and potent anti-tumor activity without the participation of IL-21R+ APC [abstract]. The Potent New Anti-Tumor Immunotherapies, Keystone Symposium. 2007.
  15. Butler MO, Hodi FS, Ng A, Murray AP, Ansén S, Berezovskaya A, Nadler LM, Hirano N. Repetitive adoptive cell transfer of long-lived CTL combined with localized tumor irradiation and systemic GM-CSF administration [abstract]. The Potent New Anti-Tumor Immunotherapies, Keystone Symposium. 2007.
  16. Hirano N, Takahashi E, Yamamoto J, Abe N, Ingle SP, Kaneoka I, Hirata T, Kimura J, Ishii T, Ogawa Y, Machida S, Suyehiro K. Volcanism in response to plate flexure. Science. 2006 Sep 8; 313(5792):1426-8.
    View in: PubMed
  17. Hirano N, Butler MO, Xia Z, Berezovskaya A, Murray AP, Ansén S, Kojima S, Nadler LM. Identification of an immunogenic CD8+ T-cell epitope derived from gamma-globin, a putative tumor-associated antigen for juvenile myelomonocytic leukemia. Blood. 2006 Oct 15; 108(8):2662-8.
    View in: PubMed
  18. Hirano N, Butler MO, Xia Z, Berezovskaya A, Murray AP, Ansén S, Nadler LM. Efficient presentation of naturally processed HLA class I peptides by artificial antigen-presenting cells for the generation of effective antitumor responses. Clin Cancer Res. 2006 May 15; 12(10):2967-75.
    View in: PubMed
  19. Butler MO, Hodi FS, Lee J-S, Murray AP, Ansén S, Berezovskaya A, Mulligan RC, Nadler LM, Hirano N. Artificial antigen presenting cells expressing HLA-A2, CD80, and CD83 generate large numbers of CD8+ antigen specific T cells for the treatment of cancer patients [abstract]. Annual Meeting of American Association for Cancer Research. 2006.
  20. Butler MO, Hodi FS, Ng A, Murray AP, Ansén S, Berezovskaya A, Nadler LM, Hirano N. A combination immunotherapy clinical trial for metastatic melanoma: Adoptive cell transfer of long-lived CTL, localized tumor irradiation, and systemic GM-CSF administration [abstract]. Cancer Immunotherapy, Cancer Research Institute. 2006.
  21. Ansén S, Butler MO, Berezovskaya A, Murray AP, Nadler LM, Hirano N. IL-21 secretion by artificial APC markedly enhances ex vivo expansion of antigen-specific CD8+ T cells with a distinct phenotype and anti-tumor immunity [abstract]. Cancer Immunotherapy, Cancer Research Institute. 2006.
  22. Yagasaki H, Yoshida N, Hirano N, Nishio N, Hama A, Wang Y, Takahashi Y, Kojima S. . Presence of HLA-DR15, a minor PNH clone, or an aplastic anemia-associated autoantibody do not predict a favorable response to immunosuppressive therapy in children with aplastic anemia [abstract]. Annual Meeting of American Society of Hematology. 2006.
  23. Ansén S, Butler MO, Berezovskaya A, Murray AP, Nadler LM, Hirano N. IL-21 secreted by APC confers robust expansion of antigen specific CD8+ T cells with distinct phenotype [abstract]. Annual Meeting of American Association for Cancer Research. 2006.
  24. Butler MO, Murray AP, Ansén S, Berezovskaya A, Mulligan RC, Nadler LM, Hirano N. Artificial antigen presenting cell (APC) expressing membranous anti-CD3 mAb, CD80, and CD83 expand CD4+ and CD8+ T Cells but not Foxp3+ regulatory T cells [abstract]. Tumor Immunology: an Integrated Perspective Conference. 2006.
  25. Butler MO, Nadler LM, Hirano N. Standardized, renewable human clinical grade artificial APC generate large numbers of long lived antigen specific cells for immunotherapy [abstract]. International Society for Cell and Gene Therapy, Japan Conference. 2006.
  26. Ansén S, Butler MO, Berezovskaya A, Murray AP, Nadler LM, Hirano N. IL-21 secretion by artificial APC markedly enhances ex vivo expansion of antigen-specific CD8+ T cells with a distinct phenotype and potent anti-tumor activity [abstract]. Tumor Immunology: an Integrated Perspective Conference, AACR Special Conference. 2006.
  27. Hirano N, Butler MO, Berezovskaya A, Nadler LM. The N-terminal but not the C-terminal CRD of galectin-8 and the presence of cellular glycosylation are required for the externalization of galectin-8 [abstract]. Annual Meeting of American Association for Cancer Research. 2006.
  28. Hirano N, Butler MO, Nadler LM. Modified antigen-presenting cells. 2006.
  29. Hirano N, Butler MO, Xia Z, Ansén S, von Bergwelt-Baildon MS, Neuberg D, Freeman GJ, Nadler LM. Engagement of CD83 ligand induces prolonged expansion of CD8+ T cells and preferential enrichment for antigen specificity. Blood. 2006 Feb 15; 107(4):1528-36.
    View in: PubMed
  30. Ren ZY, Ingle S, Takahashi E, Hirano N, Hirata T. The chemical structure of the Hawaiian mantle plume. Nature. 2005 Aug 11; 436(7052):837-40.
    View in: PubMed
  31. Butler MO, Nadler LM, Hirano N. Standardized, renewable human clinical grade aAPC generate large numbers of long lived antigen specific CTLs for immunotherapy [abstract]. Basic Aspects of Tumor Immunology II, Keystone Symposium. 2005.
  32. Hirano N, Butler MO, Guinan EC, Nadler LM, Kojima S. Presence of anti-kinectin and anti-PMS1 antibodies in Japanese aplastic anaemia patients. Br J Haematol. 2005 Jan; 128(2):221-3.
    View in: PubMed
  33. Butler MO, Hodi FS, Lee JS, Mulligan R, Nadler LM, Hirano N. Artificial Antigen Presenting Cells Generate CD8+ Antigen Specific T-Cells for Adoptive Immunotherapy: Challenges Of Clinical Translation [abstract]. Cancer Vaccines, Cancer Research Institute. 2005.
  34. Hirano N. Aplastic anemia: an autoimmune disease. Ann Rev Hematol 2005. 2005; 86-93.
  35. Hirano N. Aplastic anemia and autoantibody. Intern Med. 2004; 94:540-4.
  36. Hirano N, Butler MO, Nadler LM. 4-1BB (CD137) or CD40 signaling fails to improve the expansion of antigen specific T cells demonstrated with engagement of TCR, CD28 and CD83 ligand [abstract]. Annual Meeting of American Society of Hematology. 2004.
  37. Hirano N. Autoantibody and aplastic anemia. Hematol Front. 2004; 160:1808-11.
  38. Hirano N, Butler MO, Nadler LM. Highly efficient presentation of endogenously processed class I peptides by artificial APC for the generation of effective anti-tumor responses [abstract]. Annual Meeting of American Society of Hematology. 2004.
  39. Hirano N, Butler MO, Nadler LM. g-Globin, a tumor-associated antigen for juvenile myelomonocytic leukemia (JMML): A cell-based approach to identify tumor antigenic epitopes that are naturally processed and presented [abstract]. Annual Meeting of American Society of Hematology. 2004.
  40. Hirano N. Aplastic anemia as an autoimmune disease. Hematol Oncol. 2004; 171-5.
  41. Butler MO, Hirano N, Lee J-S, Beecham EJ, Chung M, Ripley R, Murray AP, Mulligan RC, Nadler LM. Off the shelf, GMP grade artificial APC efficiently generates large numbers of antigen specific CTLs sufficient for the treatment of cancer and infectious disease [abstract]. Annual Meeting of American Society of Hematology. 2004.
  42. Hirano N, Butler MO, Von Bergwelt-Baildon MS, Maecker B, Schultze JL, O'Connor KC, Schur PH, Kojima S, Guinan EC, Nadler LM. Autoantibodies frequently detected in patients with aplastic anemia. Blood. 2003 Dec 15; 102(13):4567-75.
    View in: PubMed
  43. Maecker B, Sherr DH, Vonderheide RH, von Bergwelt-Baildon MS, Hirano N, Anderson KS, Xia Z, Butler MO, Wucherpfennig KW, O'Hara C, Cole G, Kwak SS, Ramstedt U, Tomlinson AJ, Chicz RM, Nadler LM, Schultze JL. The shared tumor-associated antigen cytochrome P450 1B1 is recognized by specific cytotoxic T cells. Blood. 2003 Nov 1; 102(9):3287-94.
    View in: PubMed
  44. von Bergwelt-Baildon MS, Vonderheide RH, Maecker B, Hirano N, Anderson KS, Butler MO, Xia Z, Zeng WY, Wucherpfennig KW, Nadler LM, Schultze JL. Human primary and memory cytotoxic T lymphocyte responses are efficiently induced by means of CD40-activated B cells as antigen-presenting cells: potential for clinical application. Blood. 2002 May 1; 99(9):3319-25.
    View in: PubMed
  45. Tzachanis D, Freeman GJ, Hirano N, van Puijenbroek AA, Delfs MW, Berezovskaya A, Nadler LM, Boussiotis VA. Tob is a negative regulator of activation that is expressed in anergic and quiescent T cells. Nat Immunol. 2001 Dec; 2(12):1174-82.
    View in: PubMed
  46. Vonderheide RH, Butler MO, Liu JF, Battle TE, Hirano N, Gribben JG, Frank DA, Schultze JL, Nadler LM. CD40 activation of carcinoma cells increases expression of adhesion and major histocompatibility molecules but fails to induce either CD80/CD86 expression or T cell alloreactivity. Int J Oncol. 2001 Oct; 19(4):791-8.
    View in: PubMed
  47. Hirano N, Kohno J, Tsunoda S, Nishio M, Kishi N, Okuda T, Kawano K, Komatsubara S, Nakanishi N. TMC-69, a new antitumor antibiotic with Cdc25A inhibitory activity, produced by Chrysosporium sp. TC1068. Taxonomy, fermentation and biological activities. J Antibiot (Tokyo). 2001 May; 54(5):421-7.
    View in: PubMed
  48. Kinoshita K, Watanabe H, Ando Y, Katayama M, Yamamoto H, Hirano N, Yoshikuni S, Yamamoto T. Effects of subtotal resection of the fundus on development of intestinal metaplasia induced by X-ray irradiation in Donryu rats. Pathol Int. 2000 Nov; 50(11):879-83.
    View in: PubMed
  49. Takezako Y, Kanda Y, Arai C, Takezako N, Shirai Y, Hirano N, Miwa A, Togawa A. Spontaneous remission in acute type adult T-cell leukemia/lymphoma. Leuk Lymphoma. 2000 Sep; 39(1-2):217-22.
    View in: PubMed
  50. Hirano N, Hirai H. Human phospholipase C-alpha and DNA sequence encoding the same. 2000.
  51. Adachi S, Hirano N, Tanabe M, Watanabe T, Inagaki H, Ishii T. Multivariate analysis of patients with head injury using quantification theory type II--with special reference to prediction of patient outcome. Neurol Med Chir (Tokyo). 2000 Apr; 40(4):200-4; discussion 204-5.
    View in: PubMed
  52. Nakamoto T, Yamagata T, Sakai R, Ogawa S, Honda H, Ueno H, Hirano N, Yazaki Y, Hirai H. CIZ, a zinc finger protein that interacts with p130(cas) and activates the expression of matrix metalloproteinases. Mol Cell Biol. 2000 Mar; 20(5):1649-58.
    View in: PubMed
  53. Takahashi T, Hirano N, Takahashi T, Chiba S, Yazaki Y, Hirai H. Immunogene therapy against mouse leukemia using B7 molecules. Cancer Gene Ther. 2000 Jan; 7(1):144-50.
    View in: PubMed
  54. Hirano N. CTLA4Ig and transplantation immunology. J Clin Exp Med. 2000; 194:1195-200.
  55. Hara T, Hirano K, Hirano N, Tamura H, Sui H, Shibuya T, Hyogo A, Hirashio T, Tokai H, Yamashita Y, Kura K. Mutation induction by N-propyl-N-nitrosourea in eight MutaMouse organs. Mutat Res. 1999 Aug 18; 444(2):297-307.
    View in: PubMed
  56. Guinan EC, Boussiotis VA, Neuberg D, Brennan LL, Hirano N, Nadler LM, Gribben JG. Transplantation of anergic histoincompatible bone marrow allografts. N Engl J Med. 1999 Jun 3; 340(22):1704-14.
    View in: PubMed
  57. Takahashi T, Yamada K, Tanaka T, Kumano K, Kurokawa M, Hirano N, Honda H, Chiba S, Tsuji K, Yazaki Y, Nakahata T, Hirai H. A potential molecular approach to ex vivo hematopoietic expansion with recombinant epidermal growth factor receptor-expressing adenovirus vector. Blood. 1998 Jun 15; 91(12):4509-15.
    View in: PubMed
  58. Hagiwara S, Yuo A, Miwa A, Takezako N, Hirano N, Togawa A. A rare atypical myeloproliferative-disorder-like hemopathy with marked dysplasia, peripheral dominant myeloblast proliferation and extramedullary hematopoiesis was converted into typical acute myeloid leukemia with an interval of complete hematological remission. Int J Hematol. 1998 Jun; 67(4):411-6.
    View in: PubMed
  59. Hirano N. . Immuno-gene therapy. Hematopoietic stem cells. 1998.
  60. Tazuma S, Miura H, Hirano N, Hattori Y, Kajihara T, Tsuchimoto D, Miyake H, Nishioka T, Hyogo H, Nakao S, Yamashita G, Kajiyama G. A quantitative assessment of serum chylomicron by light scattering intensity: application to the intestinal fat absorption test. J Gastroenterol Hepatol. 1997 Nov; 12(11):713-8.
    View in: PubMed
  61. Kanda Y, Chiba S, Hirano N, Hirai H, Yazaki Y. Rapid progression of chronic myelomonocytic leukemia following diaminodiphenyl sulphone treatment for dermatitis herpetiformis. Int J Hematol. 1997 Oct; 66(3):383-5.
    View in: PubMed
  62. Yamada T, Hirano N, Kuroda T, Okuda Y, Itoh Y. Generation and characterization of rat monoclonal antibodies against human serum amyloid A. Scand J Immunol. 1997 Aug; 46(2):175-9.
    View in: PubMed
  63. Hirano N, Takahashi T, Takahashi T, Azuma M, Okumura K, Yazaki Y, Yagita H, Hirai H. Protective and therapeutic immunity against leukemia induced by irradiated B7-1 (CD80)-transduced leukemic cells. Hum Gene Ther. 1997 Jul 20; 8(11):1375-84.
    View in: PubMed
  64. Hirano N, Takahashi T, Takahashi T, Azuma M, Yazaki Y, Yagita H, Hirai H. Protective and therapeutic immunity against leukemia induced by irradiated B7-1 (CD80)-transduced leukemic cells. Leukemia. 1997 Apr; 11 Suppl 3:577-81.
    View in: PubMed
  65. Hirano N, Hirai H. Immuno-gene therapy against leukemia. Ann Rev Hematol 1997. 1997; 105-13.
  66. Hirai H, Hirano N. Gene therapy and hematologic malignancies. Hematol Front. 1997; 7:63-70.
  67. Kurokawa M, Tanaka T, Tanaka K, Hirano N, Ogawa S, Mitani K, Yazaki Y, Hirai H. A conserved cysteine residue in the runt homology domain of AML1 is required for the DNA binding ability and the transforming activity on fibroblasts. J Biol Chem. 1996 Jul 12; 271(28):16870-6.
    View in: PubMed
  68. Hirano N, Takahashi T, Takahashi T, Ohtake S, Hirashima K, Emi N, Saito K, Hirano M, Shinohara K, Takeuchi M, Taketazu F, Tsunoda S, Ogura M, Omine M, Saito T, Yazaki Y, Ueda R, Hirai H. Expression of costimulatory molecules in human leukemias. Leukemia. 1996 Jul; 10(7):1168-76.
    View in: PubMed
  69. Hirano N. Lymphopoiesis. Hematology. 1996; 2-7.
  70. Hirano N. Aplastic anemia, Lymphadenopathy, Paroxysmal nocturnal hematuria, Myeloproliferative disorders, Side effects of anti-cancer drugs. Internal Medicine for Pharmacists. 1996; 82-106.
  71. Hirano N, Shibasaki F, Sakai R, Tanaka T, Nishida J, Yazaki Y, Takenawa T, Hirai H. Molecular cloning of the human glucose-regulated protein ERp57/GRP58, a thiol-dependent reductase. Identification of its secretory form and inducible expression by the oncogenic transformation. Eur J Biochem. 1995 Nov 15; 234(1):336-42.
    View in: PubMed
  72. Ueno H, Hirano N, Kozutsumi H, Sasaki K, Tanaka T, Yazaki Y, Hirai H. An epidermal growth factor receptor-leukocyte tyrosine kinase chimeric receptor generates ligand-dependent growth signals through the Ras signaling pathway. J Biol Chem. 1995 Aug 25; 270(34):20135-42.
    View in: PubMed
  73. Yamagata T, Nishida J, Sakai R, Tanaka T, Honda H, Hirano N, Mano H, Yazaki Y, Hirai H. Of the GATA-binding proteins, only GATA-4 selectively regulates the human interleukin-5 gene promoter in interleukin-5-producing cells which express multiple GATA-binding proteins. Mol Cell Biol. 1995 Jul; 15(7):3830-9.
    View in: PubMed
  74. Takahashi T, Chiba S, Hirano N, Yazaki Y, Hirai H. Characterization of three erythropoietin (Epo)-binding proteins in various human Epo-responsive cell lines and in cells transfected with human Epo-receptor cDNA. Blood. 1995 Jan 1; 85(1):106-14.
    View in: PubMed
  75. Hirano N. Costimulatory molecules based immuno-gene therapy against cancer. J Clin Exp Med. 1995; 175:294-7.
  76. Sakai R, Iwamatsu A, Hirano N, Ogawa S, Tanaka T, Nishida J, Yazaki Y, Hirai H. Characterization, partial purification, and peptide sequencing of p130,the main phosphoprotein associated with v-Crk oncoprotein. J Biol Chem. 1994 Dec 30; 269(52):32740-6.
    View in: PubMed
  77. Tazuma S, Ochi H, Teramen K, Yamashita Y, Horikawa K, Miura H, Hirano N, Sasaki M, Aihara N, Hatsushika S, et al. Degree of fatty acyl chain unsaturation in biliary lecithin dictates cholesterol nucleation and crystal growth. Biochim Biophys Acta. 1994 Nov 17; 1215(1-2):74-8.
    View in: PubMed
  78. Ogawa S, Hirano N, Sato N, Takahashi T, Hangaishi A, Tanaka K, Kurokawa M, Tanaka T, Mitani K, Yazaki Y, et al. Homozygous loss of the cyclin-dependent kinase 4-inhibitor (p16) gene in human leukemias. Blood. 1994 Oct 15; 84(8):2431-5.
    View in: PubMed
  79. Hirano N, Shibasaki F, Kato H, Sakai R, Tanaka T, Nishida J, Yazaki Y, Takenawa T, Hirai H. Molecular cloning and characterization of a cDNA for bovine phospholipase C-alpha: proposal of redesignation of phospholipase C-alpha. Biochem Biophys Res Commun. 1994 Oct 14; 204(1):375-82.
    View in: PubMed
  80. Sakai R, Iwamatsu A, Hirano N, Ogawa S, Tanaka T, Mano H, Yazaki Y, Hirai H. A novel signaling molecule, p130, forms stable complexes in vivo with v-Crk and v-Src in a tyrosine phosphorylation-dependent manner. EMBO J. 1994 Aug 15; 13(16):3748-56.
    View in: PubMed
  81. Ogawa S, Toyoshima H, Kozutsumi H, Hagiwara K, Sakai R, Tanaka T, Hirano N, Mano H, Yazaki Y, Hirai H. The C-terminal SH3 domain of the mouse c-Crk protein negatively regulates tyrosine-phosphorylation of Crk associated p130 in rat 3Y1 cells. Oncogene. 1994 Jun; 9(6):1669-78.
    View in: PubMed
  82. Tazuma S, Hatsushika S, Yamashita G, Aihara N, Sasaki M, Horikawa K, Yamashita Y, Teramen K, Ochi H, Hirano N, et al. Simultaneous microanalysis of biliary cholesterol, bile acids and fatty acids in lecithin using capillary column gas chromatography: an advantage to assess bile lithogenecity. J Chromatogr B Biomed Appl. 1994 Feb 18; 653(1):1-7.
    View in: PubMed
  83. Sugimoto K, Hirano N, Toyoshima H, Chiba S, Mano H, Takaku F, Yazaki Y, Hirai H. Mutations of the p53 gene in myelodysplastic syndrome (MDS) and MDS-derived leukemia. Blood. 1993 Jun 1; 81(11):3022-6.
    View in: PubMed
  84. Hirano N. Molecular cloning and characterization of bovine and human ERp57/GRP58 complementary DNAs. 1993.
  85. Tanaka T, Shibasaki F, Ishikawa M, Hirano N, Sakai R, Nishida J, Takenawa T, Hirai H. Molecular cloning of bovine actin-like protein, actin2. Biochem Biophys Res Commun. 1992 Sep 16; 187(2):1022-8.
    View in: PubMed
  86. Hirai H, Hirano N, Yazaki Y. [Activation of ras oncogene in myelodysplastic syndrome and acute myelogenous leukemia]. Gan To Kagaku Ryoho. 1991 Jun; 18(7):1090-7.
    View in: PubMed
  87. Hirai H, Hirano N, Yazaki Y. Activation of ras oncogene in myelodysplastic syndrome and acute myelogenous leukemia. Jpn J Cancer Chem. 1991; 18:1090-7.
  88. Hirano N, Hirai H. Mutated RAS oncogene in MDS and leukemia. J Clin Exp Med. 1991; 158:260-4.
  89. Tsukamoto T, Hirano N, Iwasaki Y, Haga S, Terunuma H, Yamamoto T. Vacuolar degeneration in mice infected with a coronavirus JHM-CC strain. Neurology. 1990 Jun; 40(6):904-10.
    View in: PubMed
  90. Hirano N, Ishikawa F. Oncogene and leukemia. Hematology and Oncology. 1990; 21:1-8.
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact Human Resources at faculty_serviceshms.harvard.edu.
Hirano's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts
_
Co-Authors
_
Similar People
_
Same Department
Physical Neighbors
_